

September 3, 2015



Titan Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/03/15 -- [Titan Pharmaceuticals, Inc.](http://www.titanpharm.com) (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term drug delivery technology, announced today that Sunil Bhonsle, president, will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10 at 3:25 p.m. at the St. Regis Hotel in New York. The presentation will take place in the Louis XVI B room.

Mr. Bhonsle will review Titan's development program for Probuphine® for the long-term maintenance treatment of opioid dependence, including the recent resubmission of the New Drug Application (NDA) for Probuphine to the U.S. Food and Drug Administration. He will also provide an overview of the company's ProNeura™ for Parkinson's disease program and other upcoming milestones for 2015.

About Titan Pharmaceuticals

Titan Pharmaceuticals Inc. (OTCQB: TTNP), based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product candidate is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is ideally suited for delivering sustained, consistent levels of medication for three months or longer. Titan has granted North American commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions, such as Parkinson's disease, where maintaining consistent blood levels of a dopamine agonist may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and

uncertainties relating to the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

CONTACT:

Titan Pharmaceuticals, Inc.
President
Sunil Bhonsle
(650) 244-4990

Investors:
Stephen Kilmer
(647) 872-4849
skilmer@titanpharm.com

Media:
Susan Thomas
(619) 540-9195
stthomas@titanpharm.com

Source: Titan Pharmaceuticals, Inc.